SYRS News and Press, Syros Pharmaceuticals Inc. From 05/16/22

Three Data Readouts Expected in 2022: Data from the Safety Lead-ins of the SY-5609 Trial in Pancreatic Cancer and of the SELECT-AML-1 Phase 2 Trial; Data from the Dose Confirmation Study of SY-2101 in APL On Track to Report Data from Ongoing SELECT-MDS-1 Pivotal Trial ...

Syros Pharmaceuticals (NASDAQ:SYRS) is scheduled to announce Q1 earnings results on Monday, May 16th, before market open. The consensus EPS Estimate is -$0.47 (-104.3% Y/Y) and the consensus Revenue Estimate is $4.92M (+1.9% Y/Y). Over the last 3 months, EPS estimates have seen 2 upward revis...

BITF, CGEN, CLSN, CMRX, OTCQB:CVSI, GOED, KALA, LTRY, LUNA, MNMD, NOVN, OEG, PLX, PTE, SOHU, SSYS, SYN, SYRS, TCRT, WEJO, WIX, WRBY For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Monday, May 16, 2022 to report its first quarter 2022 financial results and provide...

Gainers: Inozyme Pharma (INZY) +15%. Clarus Therapeutics (CRXT) +10%. MedAvail (MDVL) +5%. Syros Pharmaceuticals (SYRS) +5%. Magenta Therapeutics (MGTA) +4%. Losers: AlloVir (ALVR) -10%. Rite Aid (RAD) -9%. Windtree Therapeutics (WINT) -7...

CDK12 Inhibitor Demonstrates Strong Anti-Tumor Activity as Single Agent and in Combination with a DNA Damaging Agent and a PARP Inhibitor in Models of Breast, Lung, and Ovarian Cancer On Track to Nominate CDK12 Inhibitor as Next Development Candidate in 2H 2022 Syros...

Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 89,400 shares of Syros common stock to three newly hired employees in connection with ...

Gainers: Adagio Therapeutics (ADGI) +48%. Vyant Bio (VYNT) +23%. Vir Biotechnology (VIR) +19%. Sonoma Pharmaceuticals (SNOA) +15%. Syros Pharmaceuticals (SYRS) +15%. Losers: Revelation Biosciences (REVB) -40%. UpHealth (UPH) -29%. The Valens (VLNS)...

Syros Pharmaceuticals, Inc. (SYRS) Q4 2021 Financial Results Conference Call March 15, 2022, 08:30 AM ET Company Participants Courtney Solberg - Manager, Corporate Communications and Investor Relations Nancy Simonian - Chief Executive Officer Jason Haas - Chief Financial Officer David Roth - ...

Syros Pharmaceuticals press release (NASDAQ:SYRS): Q4 GAAP EPS of -$0.38 beats by $0.08. Revenue of $78M (+1268.4% Y/Y) beats by $73.16M. Cash, cash equivalents and marketable securities as of December 31, 2021 were $143.4M. The company believes that its existing cash, cash equivalents and ma...